字号·· | 护眼
路透社

Sellas疫苗在血液癌症试验中延长生存期,股价飙升Sellas vaccine extends survival in blood cancer trial, shares surge

点「原文对照」整页切到原文,或双击某段只看那段的原文。

11月17日 —— 药物开发商Sellas Life Sciences周二表示,其针对一种血液癌症的实验性疫苗在一项晚期临床试验中帮助患者显著延长了生存期,引发其股价单日创纪录飙升。

Nov 17 - Drug developer Sellas Life Sciences said on Tuesday its experimental vaccine for a type of blood cancer helped patients live significantly longer in a late-stage trial, sparking a record one-day surge in its shares.

这种名为galinpepimut-S(简称GPS)的疫苗,在急性髓系白血病(AML)患者中进行了测试。这些患者在接受癌症治疗后处于缓解期,但无法接受骨髓或干细胞移植。

The vaccine, called galinpepimut-S or GPS, was tested in patients with acute myeloid leukemia (AML), who were in remission after cancer therapy but were unable to receive a bone marrow or stem-cell transplant.

AML是一种侵袭性的血液和骨髓癌症,疾病在治疗后复发的患者往往面临有限的治疗选择。

AML is an aggressive cancer of the blood and bone marrow, and patients whose disease returns after treatment often face limited care options.

Sellas表示,在126名患者的研究中,与最佳现有治疗相比,GPS将死亡风险降低了41%。接受疫苗治疗的患者中位生存期为24个月,而对照组为14.7个月。

In the 126-patient study, GPS cut the risk of death by 41% compared to best available treatment, Sellas said. Patients treated with the vaccine lived for a median of 24 months, versus 14.7 months for those in the control group.

该疫苗通过训练人体免疫系统寻找并攻击携带一种名为WT1蛋白的残留白血病细胞来发挥作用。

The vaccine works by training the body's immune system to find and attack leftover leukemia cells that carry a protein called WT1.

首席执行官Angelos Stergiou在电话会议上表示,对于“已经历过多线高强度化疗折磨的脆弱患者而言,在不增加全身毒性的情况下延长生命,无异于变革性的突破。”

For fragile patients "already battered by prior lines of intensive chemotherapy, delivering longer life without adding systemic toxicity would be nothing short of transformative," CEO Angelos Stergiou said on a conference call.

根据美国癌症协会的数据,预计2026年将有约22,720人被诊断患有AML,约11,500人死于该疾病。AML占成人白血病病例的1/3。

According to the American Cancer Society, about 22,720 people will be diagnosed with AML and about 11,500 are expected to die from the disease in 2026. AML accounts for 1 out of 3 leukemia in adults.

Sellas股价暴涨逾三倍至22.93美元。若涨幅保持,该公司市值将增加约31亿美元。

Sellas shares jumped more than threefold to $22.93. If gains hold, the company would add roughly $3.1 billion to its market value.

Alliance Global Partners分析师James Molloy表示,该试验结果“具有极其重要的临床意义”。“我们认为GPS应在2027年作为单药疗法获得加速批准……并且可能在治疗范式中更早地看到显著的超说明书用药情况。”Sellas计划与美国食品药品监督管理局(FDA)会面,讨论加速申报策略,目标是在2027年上半年提交批准申请。

The trial result was "incredibly clinically meaningful", said Alliance Global Partners analyst James Molloy. "We believe GPS should receive an expedited approval in 2027 as a monotherapy... and that it could see significant off-label usage earlier in the treatment paradigm as well." Sellas plans to meet with the US FDA to discuss an accelerated filing strategy, aiming to submit an approval application in the first half of 2027.

总部位于纽约的公司表示,该疫苗总体耐受性良好,未引发新的安全担忧。

The New York-based company said the vaccine was generally well tolerated and raised no new safety concerns.

阅读媒体原文 ↗